Vietnam is rapidly emerging as one of Southeast Asia's most promising genomics markets, with growing investment in precision medicine, molecular diagnostics and biotechnology driving demand for next-generation sequencing (NGS) technologies.
While Vietnam-specific market values are not widely published, industry analysis estimates the country's next-generation sequencing (NGS) market was worth US$20–30 million in 2025 and is projected to reach US$50–70 million by 2030. Growth is expected to significantly outpace many traditional diagnostics markets as genomic sequencing becomes increasingly integrated into clinical practice and biomedical research.
The market is being supported by the continued expansion of Vietnam's molecular diagnostics sector. According to IMARC Group, the country's molecular diagnostics market reached US$108.9 million in 2024 and is forecast to grow to US$195.4 million by 2033, driven by increasing adoption of advanced diagnostic technologies, precision medicine and genomic testing. (imarcgroup.com)
NGS has become one of the most transformative technologies in modern healthcare, enabling rapid analysis of DNA and RNA for applications including cancer diagnostics, inherited disease testing, pharmacogenomics, infectious disease surveillance and reproductive health. As sequencing costs continue to decline and clinical evidence expands, adoption is accelerating across hospitals, research institutes and pharmaceutical companies worldwide.
Several factors are fuelling market growth in Vietnam:
- Expansion of precision medicine and personalised healthcare programmes.
- Rising incidence of cancer and increasing demand for genomic profiling.
- Growing investment in biotechnology, life sciences and pharmaceutical research.
- Wider adoption of companion diagnostics and targeted therapies.
- Increased use of genomic technologies in infectious disease surveillance and public health.
- Falling sequencing costs, making advanced genomic testing more accessible.
- Greater collaboration between Vietnamese research institutions and international genomics organisations. (imarcgroup.com)
Vietnam's biotechnology sector is also expanding rapidly. IMARC Group estimates the country's biotechnology market reached US$3.4 billion in 2025 and is projected to grow to US$8.9 billion by 2034, creating strong demand for advanced genomic technologies, bioinformatics and molecular research platforms. (imarcgroup.com)
The global NGS market continues to grow at an impressive pace. According to IMARC Group, the market was valued at US$27.0 billion in 2025 and is expected to reach US$92.8 billion by 2034. Precision oncology, rare disease diagnosis, reproductive health and companion diagnostics remain among the fastest-growing applications for sequencing technologies. (imarcgroup.com)
Leading genomics companies including Illumina, Thermo Fisher Scientific, Roche Diagnostics, QIAGEN, BGI Genomics, Agilent Technologies, PacBio, Oxford Nanopore Technologies and Bio-Rad Laboratories continue to expand their sequencing portfolios, introducing faster, more accurate and increasingly cost-effective platforms to support clinical diagnostics and life sciences research.
As Vietnam continues to invest in precision medicine and strengthen its biomedical research capabilities, next-generation sequencing is expected to become an increasingly important component of healthcare delivery, pharmaceutical innovation and disease prevention. For suppliers of sequencing platforms, molecular diagnostics, laboratory automation, bioinformatics and genomic research technologies, Vietnam represents one of Southeast Asia's most exciting long-term growth opportunities.
